US Stock MarketDetailed Quotes
CARA Cara Therapeutics
- 0.308
- +0.003+0.92%
Trading Nov 21 14:22 ET
16.88MMarket Cap-175P/E (TTM)
0.315High0.300Low120.07KVolume0.302Open0.305Pre Close36.67KTurnover0.26%Turnover RatioLossP/E (Static)54.86MShares1.31052wk High23.68P/B14.40MFloat Cap0.24052wk Low--Dividend TTM46.79MShs Float29.647Historical High--Div YieldTTM4.92%Amplitude0.240Historical Low0.305Avg Price1Lot Size
Cara Therapeutics Stock Forum
Sign in to post a comment
$Cara Therapeutics (CARA.US)$
CSL Limited Reports 13.5% Stake in Cara Therapeutics Inc as of Oct 23 - SEC Filing
CSL Limited Reports 13.5% Stake in Cara Therapeutics Inc as of Oct 23 - SEC Filing
1
$Cara Therapeutics (CARA.US)$
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Cara Therapeutics announced disappointing results from Part A of their KOURAGE-1 study, evaluating oral difelikefalin for notalgia paresthetica (NP). The drug did not show meaningful clinical benefit over placebo at any dose, leading the company to discontinue the clinical program in NP. The Phase 2/3 trial involved 214 patients, and despite the...
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Cara Therapeutics announced disappointing results from Part A of their KOURAGE-1 study, evaluating oral difelikefalin for notalgia paresthetica (NP). The drug did not show meaningful clinical benefit over placebo at any dose, leading the company to discontinue the clinical program in NP. The Phase 2/3 trial involved 214 patients, and despite the...
3
$Cara Therapeutics (CARA.US)$
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes30/04/2024 09:00AM ET
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic a...
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes30/04/2024 09:00AM ET
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic a...
Cara Therapeutics' low P/S ratio reflects its declining revenues and bleak future growth projection. Per investors, the company's future may not yield a significant revenue improvement.
1
$Cara Therapeutics (CARA.US)$
Small position to start. I'll swing this one.
Small position to start. I'll swing this one.
5
25
$Cara Therapeutics (CARA.US)$
Potential to go higher, but will need to break 4.80 and hold above 4.60. Depending on how it does today, this could be a swing play
Potential to go higher, but will need to break 4.80 and hold above 4.60. Depending on how it does today, this could be a swing play
2
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
70794146 :